Evaxion Biotech A/S - ADR

NASDAQ:EVAX   12:03:36 PM EDT
1.82
+0.08 (+4.60%)
Products, Earnings Announcements

Evaxion Biotech Net Loss $24.5 Million For Year Ended December 31

Published: 03/22/2022 11:09 GMT
Evaxion Biotech A/S - ADR (EVAX) - FY Net Loss -24.5 Million Usd.
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update.
Expect Net Proceeds From Our Ipo, Our Fpo, Funds From Draws on Amounts Available Under Our Eib Loan and Our Existing Cash and Cash Equivalents Will Be Sufficient to Fund Our Operating Expenses and Capital Expenditure Requirements Through at Least 12 Months Subsequent to Date of Our 2021 Annual Report.
As of December 31, 2021, Cash and Cash Equivalents Were $32.2 Million As Compared to $5.8 Million As of December 31, 2020.
Research and Development Expenses Were $19.6 Million for Year Ended December 31, 2021 As Compared to $10.9 Million for Year Ended December 31, 2020.
Net Loss Was $24.5 Million for Year Ended December 31, 2021 Or ($1.26) Loss per Basic and Diluted Share As Compared to $15.0 Million, Or ($0.97) Loss per Basic and Diluted Share for Year Ended December 31, 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.